NCT03805399
Breast Cancer Type: Triple Negative
Hormone Mutations: AR+
Other Mutations: HER2, BRCA+, PI3K, AKT
Breast Cancer Tissue: Luminal androgen receptor (LAR) TNBC, Immunomodulatory (IM) TNBC, Basal-like immune suppressed (BLIS) TNBC, Mesenchymal (MES) TNBC
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy, Chemotherapy, Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic, untreated, or actively progressing CNS metastases
https://ClinicalTrials.gov/show/NCT03805399